Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population

Table 2 Odds ratios of bladder cancer patients for the CYP1A2, NAT2, SULT1A1, and UGT2B7 genotypes^a

Genotype	Patients (n = 282)	Control (n = 257)	Crude OR (95 % CI)	Adjusted OR^b (95 % CI)
CYP1A2
1A/1A	169 (59.9)	147 (57.2)	1^c	1^c
1A/1C	94 (33.3)	99 (38.5)	0.83 (0.58–1.18)	0.82 (0.57–1.17)
1C/1C	19 (6.7)	11 (4.3)	1.50 (0.69–3.26)	1.45 (0.67–3.16)
NAT2
Rapid acetylator	123 (43.6)	139 (54.1)	1^c	1^c
Intermediate acetylator	123 (43.6)	106 (41.2)	1.31 (0.92–1.87)	1.34 (0.94–1.92)
Slow acetylator	36 (12.8)	12 (4.7)	3.40 (1.69–6.81)^d	3.41 (1.69–6.87)^d
SULT1A1
1/1	218 (77.3)	201 (78.2)	1^c	1^c
1/2	59 (20.9)	52 (20.2)	1.05 (0.69–1.59)	1.03 (0.68–1.57)
2/2	5 (1.8)	4 (1.6)	1.15 (0.31–4.35)	1.23 (0.32–4.68)
UGT2B7
1/1	141 (50.0)	137 (53.3)	1^c	1^c
1/2	116 (41.1)	100 (38.9)	1.13 (0.79–1.61)	1.13 (0.79–1.62)
2/2	25 (8.9)	20 (7.8)	1.22 (0.65–2.29)	1.20 (0.63–2.26)

Data are presented as the number of patients/controls, with the percentage given in parenthesis unless indicate otherwise
OR Odds ratio, CI confidence interval
^a CYP1A2, Cytochrome P450 1A2; NAT2, N-acetyltransferase; SULT1A1, sulfotransferase 1A1; UGT 2B7, UDP-glucuronosyltransferase 2B7
^bOdds ratios were adjusted for age and gender
^cReference category
^d p value < 0.05

ISSN: 1347-4715